WG
XENE icon

Winton Group’s Xenon Pharmaceuticals XENE Stock Holding History

Winton Group’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-13,012
Closed -$132K – 1303
2019
Q1 		$132K Buy
+13,012
New +$110K ﹤0.01% 1011

Other funds holding XENE

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Winton Group's XENE Position: Q2 2019 in Review

Winton Group sold out of Xenon Pharmaceuticals (XENE) in Q2 2019, closing a stake of 13,012 shares — an estimated $132K sold.

Winton Group first reported a position in XENE in Q1 2019 and held it in 1 quarter. The position peaked at $132K in Q1 2019. 60 funds tracked by Wall St. Rank hold XENE as of Q2 2019.

  • Winton Group reported no remaining Xenon Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Winton Group sold 13,012 Xenon Pharmaceuticals shares in Q2 2019, an estimated $132K.
  • Winton Group first reported a position in Xenon Pharmaceuticals in Q1 2019 and held it in 1 quarter.
  • Winton Group's Xenon Pharmaceuticals position peaked at $132K in Q1 2019.
  • 60 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2019.

Based on Winton Group's 13F filing for Q2 2019, filed 8 Jul 2019.